Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-g5fl4 Total loading time: 0 Render date: 2024-07-26T01:03:17.179Z Has data issue: false hasContentIssue false

Chapter 35 - Autoimmune Rheumatic Disorders in Pregnancy

from Section 4 - Maternal Medicine

Published online by Cambridge University Press:  20 November 2021

Tahir Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Charles Savona Ventura
Affiliation:
University of Malta, Malta
Ioannis Messinis
Affiliation:
University of Thessaly, Greece
Sambit Mukhopadhyay
Affiliation:
Norfolk & Norwich University Hospital, UK
Get access

Summary

Autoimmune rheumatic diseases (ARDs) are chronic inflammatory systemic conditions which mainly affect women and whose onset is often during childbearing age. These diseases can be characterized by either a predominant articular involvement (chronic forms of arthritis) or by a multisystemic impairment (connective tissue diseases (CTD)). Reproductive issues such as fertility, contraception, and family planning are topics of crucial interest for women with ARDs [1]. For a long time, pregnancy has been discouraged in patients with ARDs because of the concerns about poor maternal and fetal prognosis. In the last decades, the increasing knowledge about the use of antirheumatic drugs during pregnancy and lactation has paved the way to a more effective maternal disease control, leading to the improvement of pregnancy outcomes. Pre-conception risk stratification is the key point and should be part of the physician-patient communication [2]. However, this task may be overlooked by either the rheumatologist or by the gynaecologist, yielding to an unmet need in the care of women with ARDs of childbearing age [3, 4].

Type
Chapter
Information
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Obstetrics & Maternal-Fetal Medicine
, pp. 295 - 303
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Østensen, M. Sexual and reproductive health in rheumatic disease. Nat Rev Rheumatol. 2017;13:485–93.CrossRefGoogle ScholarPubMed
Østensen, M. Preconception counseling. Rheum Dis Clin North Am. 2017;43:189–99.CrossRefGoogle ScholarPubMed
Andreoli, L, Lazzaroni, MG, Carini, C, et al. ‘Disease knowledge index’ and perspectives on reproductive issues: a nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine. 2019 Jul;86(4):475–81.Google Scholar
Clowse, MEB, Eudy, AM, Revels, J, Neil, L, Sanders, GD. Provider perceptions on the management of lupus during pregnancy: barriers to improved care. Lupus. 2019 Jan;28(1):8698. doi: 10.1177/0961203318815594CrossRefGoogle ScholarPubMed
Eudy, AM, McDaniel, G, Hurd, WW, Clowse, MEB. Fertility and ovarian reserve among women with rheumatoid arthritis. J Rheumatol. 2019 May;46(5):455–9.Google Scholar
Reggia, R, Andreoli, L, Sebbar, H, et al. An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. Rheumatol Adv Pract. 2019;3(1):rkz005.Google Scholar
Nørgård, BM, Larsen, MD, Friedman, S, Knudsen, T, Fedder, J. Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Ann Rheum Dis. 2019 Mar;78(3):328–34. doi: 10.1136/annrheumdis-2018-214619Google Scholar
Orquevaux, P, Masseau, A, Le Guern, V, et al. In vitro fertilization in 37 women with systemic lupus erythematosus or antiphospholipid syndrome: a series of 97 procedures. J Rheumatol. 2017;44:613–18.Google Scholar
Jethwa, H, Lam, S, Smith, C, Giles, I. Does rheumatoid arthritis really improve during pregnancy? a systematic review and metaanalysis. J Rheumatol. 2019 Mar;46(3):245–50. doi: 10.3899/jrheum.180226CrossRefGoogle ScholarPubMed
Lateef, A, Petri, M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am. 2017; 43:215226.CrossRefGoogle ScholarPubMed
Betelli, M, Breda, S, Ramoni, V, et al. Pregnancy in systemic sclerosis. J Scleroderma Relat Disord. 2018;3:21–9.Google Scholar
Machen, L, Clowse, MEB. Vasculitis and pregnancy. Rheum Dis Clin N Am. 2017;43:239–47.Google Scholar
Clowse, MEB, Eudy, AM, Kiernan, E, et al. The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology (Oxford). 2018;57:v9-v17.Google Scholar
Brucato, A, Tincani, A, Fredi, M, et al. Should we treat congenital heart block with fluorinated corticosteroids? Autoimmun Rev. 2017;16:1115–18.CrossRefGoogle ScholarPubMed
Chighizola, CB, Andreoli, L, Gerosa, M, et al. The treatment of anti-phospolipid syndrome; a comprehensive clinical approach. J Autoimmun. 2018; 90:127.CrossRefGoogle Scholar
Eudy, AM, Jayasundara, M, Haroun, T, et al. Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. Lupus. 2018;27:351–6.Google Scholar
Fredi, M, Lazzaroni, MG, Tani, C, et al. Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmun Rev. 2015;14:686–91.Google Scholar
Clowse, ME, Eudy, AM, Revels, J, Sanders, GD, Criscione-Schreiber, L. Rheumatologists’ knowledge of contraception, teratogens, and pregnancy risks. Obstet Med. 2018;11:182–5.Google Scholar
Birru Talabi, M, Clowse, MEB, Blalock, SJ, et al. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res (Hoboken). 2019 Aug;71(8):1132–40. 14. doi: 10.1002/acr.23724.Google Scholar
Sammaritano, LR. Contraception in patients with rheumatic disease. Rheum Dis Clin North Am. 2017;43:173–88.CrossRefGoogle ScholarPubMed
Andreoli, L, Bertsias, GK, Agmon-Levin, N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–85.CrossRefGoogle ScholarPubMed
Zbinden, A, van den Brandt, S, Østensen, M, Villiger, PM, Förger, F. Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters. Rheumatology (Oxford). 2018 Jul1;57(7):1235–42. doi: 10.1093/rheumatology/key053CrossRefGoogle ScholarPubMed
Smith, CJF, Förger, F, Bandoli, G, Chambers, CD. Factors associated with preterm delivery among women with rheumatoid arthritis and juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2019 Aug;71(8):1019–27. doi: 10.1002/acr.23730.Google Scholar
Flint, J, Panchal, S, Hurrell, A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55:1693–702.Google Scholar
Flint, J, Panchal, S, Hurrell, A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016;55:1698–702.Google Scholar
Skorpen, CG, Hoeltzenbein, M, Tincani, A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795810.Google Scholar
Andreoli, L, Crisafulli, F, Tincani, A. Pregnancy and reproductive aspects of systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29:473–9.Google Scholar
van den Brandt, S, Zbinden, A, Baeten, D, et al. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19:64.CrossRefGoogle ScholarPubMed
Østensen, M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol. 2017;10:661–9.Google Scholar
Mariette, X, Förger, F, Abraham, B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–33.Google Scholar
Clowse, ME, Förger, F, Hwang, C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–6.Google Scholar
Vinet, É, De Moura, C, Pineau, CA, et al. Serious infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors: a cohort study. Arthritis Rheumatol. 2018;70:1565–71.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×